Rockwell Medical, Inc. (NASDAQ:RMTI) Stock Short Interest Declines 49.3%

Rockwell Medical, Inc. (NASDAQ:RMTI – Get Free Report) was the target of a significant decline in short interest in the month of October. As of October 30th, there was short interest totaling 35,533 shares, a decline of 49.3% from the October 15th total of 70,068 shares. Based on an average daily volume of 24,708 shares, the short-interest ratio is currently 1.4 days. Approximately 0.9% of the shares of the company are sold short.

Rockwell Medical Stock Performance

RMTI stock traded down $0.14 during midday trading on Monday, hitting $6.88. 18,307 shares of the stock traded hands, compared to its average volume of 40,835. The firm has a market cap of $27.75 million, a P/E ratio of -4.81 and a beta of 1.75. The stock’s fifty day simple moving average is $7.80 and its 200-day simple moving average is $8.07. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.47 and a quick ratio of 2.27. Rockwell Medical has a 1-year low of $4.89 and a 1-year high of $12.90.

Rockwell Medical (NASDAQ:RMTI – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.41). Rockwell Medical had a negative net margin of 7.79% and a negative return on equity of 16.04%. The company had revenue of $19.12 million for the quarter, compared to analysts’ expectations of $18.22 million. On average, analysts expect that Rockwell Medical will post -0.90 earnings per share for the current year.

Analysts Set New Price Targets

RMTI has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Rockwell Medical in a report on Friday, September 11th. Wall Street Zen upgraded shares of Rockwell Medical to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings upgraded Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 8th. Finally, Zacks Research raised shares of Rockwell Medical from a “strong sell” rating to a “hold” rating in a research report on Thursday. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $20.00.

Read Our Latest Research Report on Rockwell Medical

Institutional Investors Weigh In On Rockwell Medical

An institutional investor recently raised its stake in Rockwell Medical stock. Renaissance Technologies LLC increased its position in shares of Rockwell Medical, Inc. (NASDAQ:RMTI – Free Report) by 36.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 639,120 shares of the company’s stock after buying an additional 170,800 shares during the period. Renaissance Technologies LLC owned about 1.62% of Rockwell Medical worth $571,000 at the end of the most recent reporting period. 23.31% of the stock is currently owned by institutional investors and hedge funds.

About Rockwell Medical

(Get Free Report)

Rockwell Medical, Inc. is a healthcare company that develops, manufactures and distributes products used in the treatment of people with kidney disease, particularly patients receiving hemodialysis. Its offerings include acid and bicarbonate concentrates used to prepare dialysis solutions, as well as related supplies and services for dialysis providers. The company has also developed pharmaceutical products for use in dialysis care. Founded in 1996, Rockwell Medical is based in the United States and serves dialysis providers in the U.S. and select international markets.

Further Reading

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.